Wilson C, Ebringer A, Ahmadi K, Wrigglesworth J, Tiwana H, Fielder M, Binder A, Ettelaie C, Cunningham P, Joannou C
Division of Biomolecular Sciences, King's College, London, United Kingdom.
Ann Rheum Dis. 1995 Mar;54(3):216-20. doi: 10.1136/ard.54.3.216.
To show molecular similarity between two sequences of Proteus mirabilis (haemolysin--ESRRAL; urease--IRRET) with HLA-DR antigens (EQRRAA) which are associated with rheumatoid arthritis (RA) and type XI collagen (LRREI), respectively; and, in patients with RA, to measure levels of antibody against a 16-mer synthetic peptide containing the ESRRAL sequence, and the haemolysin and urease proteins of Proteus mirabilis.
The homologous sequences EQRRAA and ESRRAL were modelled with Alchemy III, using the crystalline structure of DRB1*0101 (HLA-DR1). Sera from 40 patients with RA, 30 with ankylosing spondylitis (AS), and 30 controls were tested against synthetic ESRRAL peptide and the haemolysin of Proteus mirabilis by enzyme linked immunosorbent assay. Similar tests were also carried out on sera from 20 patients with RA, 40 with AS, and 15 controls, against Proteus mirabilis urease.
Molecular modelling of the homologous sequences ESRRAL/EQRRAA and IRRET/LRREI showed stereochemical similarities. Antibodies to the 16-mer synthetic peptide containing the ESRRAL sequence, the haemolysin, and urease proteins were significantly increased in RA patients compared with AS patients (p < 0.001) and healthy controls (p < 0.001). No such increases were observed with three control peptides including the EDERAA sequence of DRB1*0402 (HLA-DR4/Dw10), the haemolysin proteins of Streptococcus pyogenes and Vibrio parahaemolyticus, and the urease of Bacillus pasteurii.
The additive effect of the immune responses to the two Proteus mirabilis antigens, haemolysin (ESRRAL) and urease (IRRET), could be relevant in the aetiopathogenesis of RA.
显示奇异变形杆菌的两个序列(溶血素——ESRRAL;脲酶——IRRET)分别与类风湿关节炎(RA)相关的HLA - DR抗原(EQRRAA)和XI型胶原蛋白(LRREI)之间的分子相似性;并在RA患者中,检测针对含ESRRAL序列的16聚体合成肽、奇异变形杆菌溶血素和脲酶蛋白的抗体水平。
利用DRB1*0101(HLA - DR1)的晶体结构,用Alchemy III对同源序列EQRRAA和ESRRAL进行建模。通过酶联免疫吸附测定法,检测40例RA患者、30例强直性脊柱炎(AS)患者和30例对照的血清对合成的ESRRAL肽和奇异变形杆菌溶血素的反应。对20例RA患者、40例AS患者和15例对照的血清,也进行了针对奇异变形杆菌脲酶的类似检测。
同源序列ESRRAL/EQRRAA和IRRET/LRREI的分子建模显示出立体化学相似性。与AS患者(p < 0.001)和健康对照(p < 0.001)相比,RA患者针对含ESRRAL序列的16聚体合成肽、溶血素和脲酶蛋白的抗体显著增加。在包括DRB1*0402(HLA - DR4/Dw10)的EDERAA序列、化脓性链球菌和副溶血性弧菌的溶血素蛋白以及巴斯德芽孢杆菌的脲酶在内的三种对照肽中,未观察到这种增加。
对奇异变形杆菌的两种抗原溶血素(ESRRAL)和脲酶(IRRET)的免疫反应的累加效应,可能与RA的发病机制相关。